PMID- 21649646
OWN - NLM
STAT- MEDLINE
DCOM- 20110907
LR  - 20211020
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 165
IP  - 2
DP  - 2011 Aug
TI  - Erythropoietin enhances immunostimulatory properties of immature dendritic cells.
PG  - 202-10
LID - 10.1111/j.1365-2249.2011.04417.x [doi]
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells and play a 
      crucial role by modulating the T cell immune response against infective agents, 
      tumour antigens and alloantigens. The current study shows that differentiating 
      bone marrow (BM)-derived DCs but not fully differentiated DCs are targets of 
      erythropoietin (EPO). Indeed, DCs emerging from rat bone marrow, but not splenic 
      DCs, express the EPO receptor (Epo-R) and respond to EPO stimulation displaying a 
      more activated phenotype with increased CD86, CD40 and interleukin (IL)-12 
      expression levels and a higher allostimulatory capacity on T cells than untreated 
      DCs. Moreover, results here presented show that EPO up-regulates Toll-like 
      receptor (TLR)-4 in differentiating DCs rendering these cells more sensitive to 
      stimulation by the TLR-4 ligand lipopolysaccharide (LPS). Indeed, DCs treated 
      with EPO and then stimulated by LPS were strongly allostimulatory and expressed 
      CCR7, CD86, CD40, IL-12 and IL-23 at higher levels than those observed in DCs 
      stimulated with LPS alone. It is tempting to speculate that EPO could act as an 
      additional danger signal in concert with TLR-4 engagement. Thus, EPO, beyond its 
      erythropoietic and cytoprotective effects, turns out to be an immune modulator.
CI  - (c) 2011 The Authors. Clinical and Experimental Immunology (c) 2011 British Society 
      for Immunology.
FAU - Rocchetta, F
AU  - Rocchetta F
AD  - Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Mario 
      Negri Institute for Pharmacological Research, Bergamo, Italy.
FAU - Solini, S
AU  - Solini S
FAU - Mister, M
AU  - Mister M
FAU - Mele, C
AU  - Mele C
FAU - Cassis, P
AU  - Cassis P
FAU - Noris, M
AU  - Noris M
FAU - Remuzzi, G
AU  - Remuzzi G
FAU - Aiello, S
AU  - Aiello S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110607
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (B7-2 Antigen)
RN  - 0 (CD40 Antigens)
RN  - 0 (Ccr7 protein, rat)
RN  - 0 (Immunologic Factors)
RN  - 0 (Interleukin-23)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Receptors, CCR7)
RN  - 0 (Receptors, Erythropoietin)
RN  - 0 (Toll-Like Receptor 4)
RN  - 11096-26-7 (Erythropoietin)
RN  - 15UQ94PT4P (Darbepoetin alfa)
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
MH  - Animals
MH  - B7-2 Antigen/biosynthesis
MH  - Blotting, Western
MH  - Bone Marrow Cells/metabolism
MH  - CD40 Antigens/biosynthesis
MH  - Cell Differentiation
MH  - Darbepoetin alfa
MH  - Dendritic Cells/*immunology/metabolism
MH  - Erythropoietin/*analogs & derivatives/immunology/metabolism/pharmacology
MH  - *Immunologic Factors/metabolism/pharmacology
MH  - Interleukin-12/biosynthesis
MH  - Interleukin-23/biosynthesis
MH  - Lipopolysaccharides/immunology
MH  - Polymerase Chain Reaction
MH  - Rats
MH  - Rats, Inbred BN
MH  - Receptors, CCR7/biosynthesis
MH  - Receptors, Erythropoietin/genetics/metabolism
MH  - Toll-Like Receptor 4/biosynthesis/genetics
PMC - PMC3142645
EDAT- 2011/06/09 06:00
MHDA- 2011/09/08 06:00
PMCR- 2012/08/01
CRDT- 2011/06/09 06:00
PHST- 2011/06/09 06:00 [entrez]
PHST- 2011/06/09 06:00 [pubmed]
PHST- 2011/09/08 06:00 [medline]
PHST- 2012/08/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2249.2011.04417.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2011 Aug;165(2):202-10. doi: 10.1111/j.1365-2249.2011.04417.x. 
      Epub 2011 Jun 7.